Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck
- 31 October 2007
- journal article
- research article
- Published by Elsevier BV in Radiotherapy and Oncology
- Vol. 85 (1), 24-28
- https://doi.org/10.1016/j.radonc.2007.06.007
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Role of Epidermal Growth Factor Receptor Pathway–Targeted Therapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and NeckJournal of Clinical Oncology, 2006
- Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and NeckThe New England Journal of Medicine, 2006
- Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group StudyJournal of Clinical Oncology, 2005
- Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and NeckJournal of Clinical Oncology, 2005
- Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in CancerJournal of Clinical Oncology, 2005
- Blockade of epidermal growth factor receptor (EGFR) activityCritical Reviews in Oncology/Hematology, 2005
- Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer TherapyThe Journal of Immunology, 2004
- The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neckInternational Journal of Radiation Oncology*Biology*Physics, 2004
- Epidermal growth factor receptors as a target for cancer treatment: The emerging role of IMC-C225 in the treatment of lung and head and neck cancersSeminars in Oncology, 2002
- Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With CisplatinJournal of Clinical Oncology, 2000